Clinical Trial: NCT03194893
A Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2026-10-09 |
Study Overview
Brief Summary
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
Official Title
A Multicenter, International, Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Conditions
Neoplasms
Intervention / Treatment
- Drug: Alectinib
- Drug: Crizotinib
Other Study ID Numbers
- BO39694
- 2017-000207-24
- 2017
Start Date (Actual)
2017-07-05
Primary Completion Date (Actual)
2025-09-18
Study Completion Date (Actual)
2025-09-18
Enrollment (Actual)
50
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Hoffmann-La Roche |
| Information Provided By: | Hoffmann-La Roche |
| Last Update Posted: | 2026-10-09 |
Study Overview
Brief Summary
The purpose of this study is to provide continued treatment with alectinib or crizotinib as applicable to participants with ALK- or RET positive cancer who were previously enrolled in any Roche-sponsored alectinib study and who are deriving continued clinical benefit from alectinib or crizotinib in the parent trial at the time of parent trial closure.
Official Title
A Multicenter, International, Rollover Study of Alectinib in Patients With Anaplastic Lymphoma Kinase (ALK)-Positive or Rearranged During Transfection (RET)-Positive Cancer
Conditions
Neoplasms
Intervention / Treatment
- Drug: Alectinib
- Drug: Crizotinib
Other Study ID Numbers
- BO39694
- 2017-000207-24
- 2017
Start Date (Actual)
2017-07-05
Primary Completion Date (Actual)
2025-09-18
Study Completion Date (Actual)
2025-09-18
Enrollment (Actual)
50
Study Type
Interventional
Phase
Phase 3